Starry syndicate powers $165M bet on in vivo CAR-T therapies, enabling Penn spinout Capstan to set sail, page-8

Hi BigDaniel,

I reread what I wrote, and i didn't express myself very well at all.

At the time, PTX got the gig despite being a small Australian company not just because SYC is so charismatic and was in the right place at the right time. It's because picking winners at that stage is probably a bit of a lottery. You never know if there will be a problem with translation to clinical arena. Big Pharma can't snap up everything, it's massive.

MD Anderson seems to have hit this snag with their antibody treatment during the clinical phase, in particular with persistence and requirement for re-treatment. Teaming up with us allows them still progress all of their secret IP, but now seeing if our platform will solve their problem which ( in my uneducated opinion) I suspect it will.

Again, lots of shovels are going to be sold.